breast cancer
Conditions
Interventions
administration with paclitaxel and bevacizumab paclitaxel 90mg/m2 day1,8,15 Bevacizumab 10mg/kg day1,15 1cycle for 21days continue to progression
Sponsors
kyoto prefectural university of medicine
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)histologically confirmed breast cancer 2)age more than 20 and below 80 3)PS(ECOG)0-1 4)survival period more than 6 months 5)no effect remain from prior chemotherapy 6)adequate organ function WBC>=4000/mm3 Neu>=2000/mm3 Hb>=9.0g/dL Plt>=100000/mm3 sT-Bil<=1.5mg/dL AST<=100IU/L ALT<=100IU/L Cr>=60ml/min 7)written informed consent
Exclusion criteria
Exclusion criteria: 1)be pregnant or possible to pregnancy 2)with active breast cancer 3)with severe complications 4)with uncontrolled pleural effusion,ascites and edema 5)with brain metastasis 6)doctor's decision not to be registered to this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the rates of change for Ktrans using DCEMRI from first time to second time | — |
Secondary
| Measure | Time frame |
|---|---|
| progression free survival | — |
Countries
Japan
Contacts
Public Contactkatsuhiko nakatsukasa
kyoto prefectural university of medicine Dept of Endocrine and Breast surgery
Outcome results
None listed